Lichen Sclerosus Presenting as Vitiligo: A Case Series

Hind Al-Mohanna1* and Ahmed Al-Issa2

1Senior Registrar Dermatologist, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
2Consultant Dermatologist and Laser Therapy, National Center for Vitiligo and Psoriasis, Riyadh, Saudi Arabia.

Corresponding author
Hind Al-Mohanna, Senior Registrar DermatologistDepartment of Dermatology, Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia. Email: mohannahind@gmail.com

Submitted: 21 June 2017; Accepted: 28 July 2017; Published: 05 Aug 2017

Abstract
Depigmenting skin lesions have a limited differential in dermatology. Although the depigmenting process of vitiligo can be clinically striking, it is at best a cosmetic issue, and may or may not be indicative of other pertinent autoimmune process. However, the early diagnosis of lichen sclerosus (LS) is of the utmost importance, since it is associated with potentially severe pain, disfigurement and relatively increase risk of squamous cell carcinoma. We present a series of biopsy proven five cases of LS that clinically presented as vitiligo.

Introduction
LS is a chronic inflammatory dermatosis that classically presents with chalk-white plaques, epidermal atrophy and follicular plugging. Recalcitrant genital cases may result in severe pain and dysfunction [1]. Also, due to its association with squamous cell carcinoma, it is of utmost importance to obtain early recognition and diagnosis of LS [2]. Early intervention and therapy is life-altering [2]. On the other hand, vitiligo is the loss of Melanocytes resulting from cytotoxic T cells in genetic predisposed individuals [3]. Although it presents clinically with depigmented patches, the delay in its diagnosis does not portend a poor prognosis [4]. Unlike LS, it is not associated with scarring, dyspareunia, dysuria, intractable pruritus or squamous cell carcinoma [4]. Also, the first line therapy for both vitiligo and LS are similar, which is classically topical steroids [1,5]. Without a biopsy to confirm the diagnosis, the cutaneous depigmentation may be treated, but the underlying risks may be left unaddressed indefinitely. Therefore, it is our recommendation that any depigmented patch in mucosal skin warrants a biopsy to differentiate conclusively between LS and vitiligo.

Case Series
Case 1
Miss A, a 5-year-old girl presented with depigmented patches on the genetalia. Initially, she was given clobetasol propionate 0.05% ointment (Dermovate) and showed some improvement. On a subsequent visit, the girl started to complain of pruritus. Accordingly, Dermovate ointment was hold and skin biopsy was taken. The result of the biopsy was consistent with LS.

Case 2
Mrs B, a 28-year-old married lady presented to our clinic with three years history of white patches over the face, upper and lower limbs, and trunk. At that time she was given clobetasol propionate 0.05% ointment (Dermovate) and showed some improvement. On a subsequent visit, the girl started to complain of pruritus. Accordingly, Dermovate ointment was hold and skin biopsy was taken. The result of the biopsy was consistent with LS.

Case 3
Miss C, an 11-year-old girl came with depigmented spots on the thigh and peri-anal area. The differential diagnosis includes vitiligo and LS. Skin biopsy was taken. Microscopic examination revealed intact hyperpigmented epidermis. The dermis exhibits heavy sclerosis and band like chronic inflammatory infiltrate with some scattered melanophages. LS diagnosis was made.

Case 4
Mr. D, a 23-year-old single male presented to our clinic with two years history of hypopigmented patches on the left side of the neck with thick texture and violaceous colored border. The differential diagnosis includes vitiligo and LS. Skin biopsy was taken. Microscopic examination revealed intact hyperpigmented epidermis. The dermis exhibits heavy sclerosis and band like chronic inflammatory infiltrate with some scattered melanophages. LS diagnosis was made.

Case 5
Miss E, a 4-year-old girl came with hypopigmentation over the labia majora. Vitiligo and LS were considered in the differential diagnosis. Skin biopsy confirmed LS.

Discussion
LS of the mucosal skin is a debilitating disorder [6]. Although it may present initially with hypo- or depigmented patch of skin, one is obligated to biopsy such a lesion to provide a definitive diagnosis [6]. In such a case, vitiligo is a diagnosis of exclusion [6]. There have also been other previous reports that LS can masquerade as other diseases, such as early mycosis fungoides [6]. Only a biopsy is sufficient to
differentiate between LS and cutaneous T cell lymphoma [6]. Despite a pre-existing family history of vitiligo, one of our patients had a biopsy of lesion that classically presents with the phenotype of vitiligo, which histopathologically showed LS. This further emphasizes that it is imperative to biopsy a clinically suspicious lesion prior to the introduction of therapy. Only with proper diagnosis can an appropriate therapeutic course be implemented.

LS has also been shown to clinically simulate lichen planus [7]. It is also pertinent that LS can overlap with morphea (localized scleroderma) [8]. Classically, LS presents with a band-like lichenoid infiltrate at the dermo-epidermal junction, compact hyperkeratosis and prominent papillary dermal edema, which eventually results in homogenous fibrosis. This histopathological picture is characteristically different from the scenario associated with vitiligo. Since they are very different, one is obligated to do a biopsy, since the treatment approaches and resulting consultations may differ.

It is important to know that although topical calcineurin inhibitors have been shown to be efficacious in both vitiligo and LS, their use in a case of biopsy-proven LS may be discouraged [1,9]. The FDA added a black-box warning to topical calcineurin inhibitors and their connection to neoplasia, which presents a clinical conundrum [10]. Since LS is a chronically debilitating disease, the long term use of the topical calcineurin inhibitors may pose a theoretical, albeit important, risk of lowering the threshold for the development of squamous cell carcinoma [2,10].

Furthermore, the frequency of autoimmune diseases in those suffering from vitiligo is increased [11]. These autoimmune diseases include autoimmune thyroiditis, diabetes mellitus, pernicious anemia, systemic lupus erythematosus, and Addison disease [11]. Therefore, it is advisable to investigate for these medical illnesses in patients with vitiligo for early detection and appropriate consultations [11]. Additionally, there is increased incidence of auto-immune antibodies in LS and an association with auto-immune disease such as vitiligo [12,13].

In conclusion, this case series identifies that LS can clinically mimic vitiligo. Therefore, all depigmented mucosal lesion should be biopsied to allow for the proper diagnosis. Furthermore, treating all depigmented patches as vitiligo, without a conclusive biopsy, may delay the diagnosis of LS, which potentially could have devastating consequences.

References
1. Fistarol SK, Itin PH (2013) Diagnosis and treatment of lichen sclerosus: an update. Am J Clin Dermatol 14: 27-47.
2. Gutiérrez-Pascual M, Vicente-Martín FJ, López-Esteban JL (2012) Lichen sclerosus and squamous cell carcinoma. Actas Dermosifiliogr 103: 21-28.
3. Malhotra N, Dytoc M (2013) The pathogenesis of vitiligo. J Cutan Med Surg 17: 153-172.
4. Halder RM, Chappell JL (2009) Vitiligo update. Semin Cutan Med Surg 28: 86-92.
5. Korobko IV (2012) Review of current clinical studies of vitiligo treatments. Dermatol Ther 25 Suppl 1: 17-27.
6. Citarella L, Massone C, Kerl H, Cerroni L (2003) Lichen sclerosus with histopathologic features simulating early mycosis fungoides. Am J Dermatopathol 25: 463-465.
7. Corbalán-Vélez R, Pérez-Ferriols A (2001) Lichen sclerosus et atrophicus affecting the wrists and left ankle and clinically simulating lichen planus. Cutis 67: 417-419.
8. Kar BR, Dash K (2014) Co-existence of Lichen Sclerosus Atrophicus and Morphea Along Lines of Blaschko. Indian J Dermatol 59: 77-79.
9. Wong R, Lin AN (2013) Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol 52: 491-496.
10. Siegfried EC, Jaworski JC, Hebert AA (2013) Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 14: 163-178.
11. Nejad SB, Qadim HH, Nazeman L, Fadaei R, Goldust M (2013) Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. Pak J Biol Sci 16: 570-574.
12. Weisberg EL, Le LQ, Cohen JB (2008) A case of simultaneously occurring lichen sclerosus and segmental vitiligo: connecting the underlying autoimmune pathogenesis. Int J Dermatol 47: 1053-1055.
13. Guerrero C, Manco S, Paradisi A, Capizzi R, Fossati B, et al. (2008) Extragenital lichen sclerosus and atrophicus treated with topical steroids and retinoids in a child with vitiligo. Int J Immunopathol Pharmacol 21: 757-759.